Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending September 30, 2022 was -8.82 (a -30.35% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA increased by 62.57%
- Annual Net Debt/EBITDA for 2021 was -1.53 (a -656.85% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was 0.27 (a -83.68% decrease from previous year)
- Annual Net Debt/EBITDA for 2019 was 1.68 (a -19.07% decrease from previous year)
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of BridgeBio Pharma, Inc.
Most recent Net Debt/EBITDAof BBIO including historical data for past 10 years.Interactive Chart of Net Debt/EBITDA of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | -8.82 | -12.66 | -6.15 | – |
| 2021 | -5.42 | -5.36 | -5.98 | -2.67 | -1.53 |
| 2020 | 1.02 | 1.94 | 3.01 | 4.32 | 0.27 |
| 2019 | 5.67 | 8.45 | 0.0 | 0.0 | 1.68 |
| 2018 | – | – | 0.0 | 0.0 | 2.08 |
| 2017 | – | – | – | – | -1.19 |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology